Bibliographic Details
| Title: |
665P Safety, PK, immune activation, and clinical outcomes with RBS2418 treatment, an oral ENPP1 inhibitor, alone or in combination with pembrolizumab in advanced solid tumors. |
| Authors: |
Marron, T.1 (AUTHOR), Segar, J.2 (AUTHOR), Berlin, J.D.3 (AUTHOR), Boccia, R.4 (AUTHOR), Spira, A.I.5 (AUTHOR), Powderly, J.6 (AUTHOR), Chen, C.7 (AUTHOR), Wainberg, Z.A.8 (AUTHOR), Schanzer, J.M.9 (AUTHOR), Glenn, J.10 (AUTHOR), Klumpp, K.11 (AUTHOR), Csiki, I.12 (AUTHOR), Misleh, J.G.13 (AUTHOR) |
| Source: |
Annals of Oncology. 2024 Supplement 2, Vol. 35, pS523-S523. 1p. |
| Database: |
Academic Search Ultimate |
